Authors
Latest:
The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade GliomasMark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.
Latest:
Frontline Bevacizumab in GlioblastomaMark R. Gilbert, MD, reviews the trial design and findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.
Latest:
Blinatumomab Plus Chemotherapy Improves Survival in Ph-Negative B-ALLMark R. Litzow, MD, discusses the findings from the ECOG-ACRIN E1910 trial which evaluated blinatumomab added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.
Latest:
A Bispecific Immunotherapy for the Treatment of MelanomaMark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.
Latest:
Dr. Mark Robson on How DNA-Damaging Agents Function in Treating Breast CancerMark Robson, MD, clinic director of the Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, talks about how DNA-damaging agents function in treating breast cancer.
Latest:
Approaches for Transitioning to Multidisciplinary Cancer Care TeamsMark S. Soberman, MD, MBA, FACS, 2017-2018 president of the Association of Community Cancer Centers (ACCC), discusses various approaches that can be used to integrate multidisciplinary healthcare programs into various healthcare settings, following a panel discussion during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
Latest:
The Learning Curve for Minimally Invasive Surgery in Gastrointestinal CancersMark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the learning curve for minimally invasive surgery in gastrointestinal cancers.
Latest:
Advice for Community Oncologists who Treat Patients with NSCLCMark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.
Latest:
The Future of Biomarkers in Prostate CancerMark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the future of biomarkers in prostate cancer.
Latest:
SPOTLIGHT Shines on Inadequacy of Standard Imaging in Prostate CancerMark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.
Latest:
Exploring the Use of Liquid Biopsies in Smoldering Multiple MyelomaMark W. Bustoros, MD, a postdoctoral fellow at Dana-Farber Cancer Institute, Harvard Medical School, discusses ongoing research exploring the use of liquid biopsies in patients with smoldering multiple myeloma.
Latest:
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic LeukemiaMark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.
Latest:
Case 4: Later Lines of Therapy for Patients With Recurrent HCCExpert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.
Latest:
Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLCMartin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.
Latest:
Future Directions for MCL Following Results From the TRIANGLE StudyMartin Dreyling, MD, discusses the next steps for research with ibrutinib in the mantle cell lymphoma space following the presentation of data from the phase 3 TRIANGLE study.
Latest:
H3B-6527 Demonstrates Tolerability in Phase I Trial for Patients With Advanced HCCMartin E. Gutierrez, MD, director, Drug Discovery/Phase I Unit, and co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the early findings for H3B-6527, an FGFR4 inhibitor, as a treatment of patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma
Latest:
Results for Durvalumab in the Second-Line Treatment of NSCLCMartin Gutierrez, MD, director, drug discovery/phase I unit, medical oncologist, thoracic and gastrointestinal oncology, John Theurer Cancer Center, discusses results for durvalumab (Imfinzi) for the treatment of non-small cell lung cancer.
Latest:
Meeting Unmet Needs for Patients With RCCMartin H. Voss, MD, discusses the trajectory of the advanced renal cell carcinoma treatment landscape and provides clinical advice to community oncologists.
Latest:
Common Implications in Treating Patients With Advanced Hodgkin LymphomaMartin Hutchings, MD, PhD, senior consultant in the Department of Hematology at the Copenhagen University Hospital, discusses common implications in treating patients with advanced stage Hodgkin lymphoma. Trials rarely perform subgroup analyses, and when they do, it is common for researchers to come across particular biases in the selected subgroups.
Latest:
Phase III SQUIRE Trial in Patients With NSCLC Treated With NecitumumabMartin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial in patients with non-small cell lung cancer (NSCLC) treated with necitumumab.
Latest:
Results of the SELECT Trial in Thyroid CancerMartin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.
Latest:
Results for ABT-414 in Brain CancerMartin van den Bent, MD, Erasmus MC Cancer Center, discusses the results from the ABT-414 trial for patients with brain cancer.
Latest:
The Changing View of Anti-HER2 TherapiesMartine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the changing view of anti-HER2 therapies for patients with breast cancer.
Latest:
Efficacy of Lanreotide for the Treatment of Neuroendocrine TumorsMartyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.
Latest:
After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?Targeted Therapies in Oncology spoke with Martin J. Edelman, MD, do uncover what is next for small cell lung cancer after PD-1 inhibitor indication have been withdrawn.
Latest:
A New Concept to Broaden Access to Molecular TestingDuring a 2013 discussion on treating NSCLC, a group of oncologists were asked what share of cancer patients have access to molecular testing. The answers varied: One said he guessed 40% to 50%, another said "a large minority."
